ClinicalTrials.gov
public full text
Public Domain
JACTAX LD Drug Eluting Stent Trial
Prospective, multi-center, randomized trial. A maximum of 130 patients will be enrolled, in a 2:1 ratio to receive either the JACTAX LD stent or the TAXUS™ Libertè™ stent to evaluate the efficacy of the product.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- EPASS Versus Uncovered Duodenal Stent for Unresectable Malignant Gastric Outlet Obstruction.#854479
- Safety and Efficacy of the ZoMaxx™ Drug-Eluting Stent System in Coronary Arteries#1008824
- Evaluation of the First, Second, and New Drug-Eluting Stents in Routine Clinical Practice#862687
- A Randomized, Double-blind Study to Assess Paclitaxel-eluting Stents in Treatment of Longer Lesions#854047
- A Study of the TAXUS Liberté Stent for the Treatment of de Novo Coronary Artery Lesions in Small Vessels#901518
Record · ID 1228958
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive